

Note: This document has been automatically translated using a machine translation tool.

Please be advised that the content of this document has been generated by an automated system. It is important to be aware that machine translations may not fully capture the original meaning, context, or cultural nuances of the text. The original document can be found here

<https://www.med.uio.no/klinmed/forskning/sentre/seraf/publikasjoner/rapporter/2022/seraf-arsrapport-2021.html>

Please treat this document as an informative reference, but exercise caution when relying solely on its content.

# SERAF

## annual report 2021



UiO : **Institutt for klinisk medisin**  
Det medisinske fakultet

# Contents

---

- Preface .....1
- SERAF highlights in 2021 .....1
- Introduction .....2
  - Brief history and status at the start of 2021 .....2
  - Employees .....3
  - Purpose and objectives .....4
  - Core tasks .....4
- Research and collaboration.....5
  - SERAF's center grant from the Directorate of Health.....5
  - Drug-assisted rehabilitation (LAR), guidelines and AgeSUD .....6
  - Evaluation of Heroin Assisted Treatment (HAT) and quality of life in HAT .....6
  - Naloxone nasal spray; overdose antidote .....6
  - PriSUD .....7
  - Opioid painkillers and POINT .....7
  - Various smaller projects, activities and collaborations .....7
  - Collaboration (national and international).....8
  - User participation .....8
- Outreach and communication .....8
  - Further education courses and seminars .....8
  - Doctoral theses .....8
  - E-learning and video.....9
  - SERAF as a consultation body in 2021.....9
- Publications.....10
  - Reports and knowledge summaries .....10
  - Scientific articles in 2021.....10

## Foreword

---

2021 was a year that was still affected by Covid-19, but also a longer period of fairly normal activity. Several new projects were established and got off to a good start, while other projects were more in the ordinary operational phase. Overall, the academic activity was extensive and varied, and SERAF researchers contributed to around 50 published articles.

For various practical reasons, the annual report for 2021 was not completed until 2023.

Thomas Clausen  
Professor, Dr.med.  
Head of SERAF

## SERAF highlights in 2021

---

- In 2021, SERAF was awarded several external research grants related to our initiatives. Funding related to the heroin-assisted treatment (HAB) project was awarded by the DAM Foundation and focuses on quality of life among patients in heroin-assisted treatment. SERAF has been awarded new funding from the Norwegian Directorate of Health to evaluate a new national guideline for OMT, and increased funding for the naloxone project in 2021 means that more municipalities and target groups will be included in the project.
- A resource-intensive process in 2021 has been to ensure a prepared and coordinated start-up of the large collaborative project led by SERAF, which will evaluate heroin-assisted treatment starting in 2022. Plans have been made for extensive data collection via online forms and TSD in collaboration with partners at OUS and Helse Bergen.
- In 2021, SERAF appointed several new research fellows and researchers in the various projects who will contribute further to SERAF's academic activities in the coming years. Several projects are behind publications and activities that have been featured in national media.

## Introduction

---

This annual report aims to summarize SERAF's activities in 2021 and provide an overview of SERAF's organization and employees, as well as our research areas, initiatives and results.

Please visit our website at [www.seraf.uio.no](http://www.seraf.uio.no).

2021 was also characterized by the Covid-19 pandemic in several ways, including long periods of working from home for SERAF's employees and many cancelled events. Despite this, we at SERAF have largely managed to maintain our professional activities as planned.

### Brief history and status at the start of 2021

The Center for Substance Abuse and Addiction Research (SERAF) is a university-affiliated research center for clinical substance abuse research. For more than 20 years, the center has received an annual grant from the Norwegian Directorate of Health to be a national academic environment and to contribute knowledge to the Directorate of Health on drug-assisted rehabilitation (LAR) and other contributions on clinical issues in the field of substance abuse.

In the fall of 2007, the center was established in its current form following a grant from the Research Council of Norway on behalf of the Ministry of Health and Care Services, as part of the escalation plan for the field of substance abuse. The assignment through this grant partly coincided with the assignment from the Norwegian Directorate of Health; to increase knowledge in the field through research and dissemination. During this period, SERAF consolidated its position as the country's foremost academic environment in our thematic areas.

In 2018, the grant from NFR ended after 10 years, and SERAF has been in a significant restructuring phase over the past couple of years. We have gone from having a large 10-year grant, with a broad focus on increasing knowledge in the field of substance abuse, to a new situation where we have more and new external project grants from NFR, the Norwegian Directorate of Health and Helse-Sørøst. SERAFS' external research funding is linked to several ongoing initiatives and ongoing research projects that will be described in this annual report. From having a clear academic focus on "breadth" in the period 2008-2018, our academic focus today is somewhat more pointed and focused into the specific externally funded projects.

At the beginning of 2022, SERAF has approximately 28 scientific employees or associates, and an administration of 2 people.



Photo from SERAF fall seminar in 2021

## Employees

Name	Title	Project
Bech, Anne	Researcher	LAR
Bukten, Anne	Researcher	PriSUD
Bruun Ericson, Øystein	scholarship holder	Naloxone
Clausen, Thomas	Center Manager / Professor	LAR, Naloxone, HAB, Miscellaneous
Eide, Desiree	Researcher	Nalokson, HAB
Handal, Marte	Researcher	POINT
Hamina, Aleksii	Researcher	Opioid painkillers
Høiseth, Gudrun	Researcher (10%)	Toxicology, miscellaneous
Landheim, Anne	Researcher (5%)	Substance abuse and psychiatry
Lien, Lars	Researcher (5%)	Substance abuse and psychiatry
Lobmaier, Philipp	Researcher (20%)	Nalokson, LAR
Lokdam, Nicoline	scholarship holder	PriSUD
McDonald, Rebecca	Researcher	LAR
Mørland, Jørg	Professor Emeritus	Toxicology, miscellaneous
Nestvold, Håkon Høydal	scholarship holder	POINT
Riksheim Stavseth, Marianne	Researcher/statistician	PriSUD
Sarfi, Monica	Researcher/psychologist	Children of mothers with substance abuse challenges
Skjærvø, Ingeborg	Postdoc	PriSUD
Skurtveit, Svetlana	Professor II (20%)	POINT, painkiller, LAR
Solli, Kristin Klemmetsby	Researcher (20%)	Naltrekson
Sugahara, Gustavo	Researcher	AgeSUD, LAR
Svendsen, Vegard	scholarship holder	PriSUD
Tjagvad, Christian	Researcher (40%)	HAB, LAR
Todd, John	Postdoc	AgeSUD, LAR
Tverborgvik, Torill	Postdoc	PriSUD

Waal, Helge	Professor Emeritus	LAR, various
Welle-Strand, Gabrielle	Researcher/doctor	Parents with substance abuse challenges, LAR
Wüsthoff, Linda Elise Couesurel	Associate professor (20%)	HAB, various
Lillevold, Pål Henrik	Advisor	Administration
Oldervoll, Ann	Senior consultant /project coordinator	Administration

SERAF's employee group is interdisciplinary, with expertise in addiction medicine, psychiatry, psychology, epidemiology, statistics, social work, criminology, etc.

Our research methods are primarily quantitatively oriented, where register-based research is a key methodological approach, but our research also includes qualitative methods and eHealth methodology.

### Purpose and objectives

SERAF's purpose is to help ensure that substance abuse treatment in Norway is based on evidence-based principles and that substance abuse treatment is best adapted to the needs of the patients in Norwegian substance abuse treatment. Through improved treatment services, it is expected that patients with substance abuse disorders will have better health, quality of life and be better able to achieve their goals in life.

The approaches used in the field of substance abuse and therefore included in SERAF's mission include research into prevention, harm reduction and various forms of substance abuse treatment.

#### SERAF shall

- contribute to developing the knowledge base in substance abuse treatment in Norway, through clinic-based substance abuse research, with a focus on increasing understanding of the types of treatment and interventions that provide relevant and good treatment results.
- contribute to a knowledge base based primarily on the Norwegian situation, substance abuse treatment and measures in the substance abuse field.
- focus on Nordic cooperation and comparison and help to establish a knowledge base on common features, differences and effects of Nordic substance abuse treatment.
- participate in relevant national and international collaborations, both as a leading main partner and as a participating partner.

#### Core tasks

- Development of new knowledge through research
- Skills development in the service sector and among different target groups
- Dissemination of research-based knowledge in different formats
- SERAF's research includes research on the prevalence of substance use disorders, on risk factors for the development of substance use disorders, on treatment methods and their effects, and we contribute to the development of new treatment methods.
- SERAF will help to ensure that the knowledge base based on SERAF's and others' research is disseminated in the field through teaching and outreach activities.




## Research and collaboration

SERAF's activities are mainly externally funded. Projects and employees are organized in a common center model, under a uniform professional management and with a common local administration.

As the overview below shows, SERAF's main activity is linked to several different projects and external grants

- 1. Center assignment from the Directorate of Health**
  - a. National academic environment within clinical drug and alcohol research
  - b. Drug-assisted rehabilitation (LAR) etc.
  - c. Evaluation of new LAR guidelines
- 2. Naloxone nasal spray, as part of the National Overdose Strategy, funded by HDir**
  - a. Distribution project
  - b. Evaluation and research project
- 3. Evaluation of Heroin Assisted Treatment (HAB), funded by HDir on behalf of HOD. Research on quality of life in HAB funded by the DAM Foundation**
- 4. Abuse of opioid painkillers (POINT), funded by NFR.**
  - a. Opioid analgesics and mortality (HDir)
- 5. PriSUD; Crime, prison and substance abuse, funded by HSØ and NFR**
  - a. Norwegian sub-project
  - b. Nordic sub-project
- 6. AgeSUD; a cohort-based study with follow-up of people in substance abuse treatment with a focus on aging, funded by HSØ.**
  - a. LAR
  - b. Inpatient treatment
- 7. Various smaller projects and collaborations, including eHealth**
  - a. Evaluation of new guidelines for LAR, funded by HDir



### SERAF's center grant from the Directorate of Health

This is SERAF's core appropriation, which contributes to our local administration, our two externally funded professorships (100% + 20%) and a research position. With this appropriation, SERAF is tasked with producing an annual national status report on DAR and disseminating professional updates and skills enhancement in the field through teaching and courses, among other things. The status survey for LAR is conducted annually as a national survey in collaboration with all

OMT interventions in Norway. The status reports are a useful tool for everyone working in the field of OMT and decision-makers. The reports include regional differences in clinical practice and treatment outcomes and assessments of what will be evidence-based and adequate adjustments to treatment in the future.

### Drug-assisted rehabilitation (LAR), guidelines and AgeSUD

Research on OMT and the effects of treatment has been a key research topic for a number of years at SERAF, which has resulted in several Master's theses and PhD work at SERAF. From around 2011, work began on collecting data from a cohort of patients who started substance abuse treatment, including OMT, under the project name NorCOMT. This data collection, which took place in the period 2012-2016 and included more than 500 patients who started a new substance abuse treatment episode with a follow-up interview after 12 months, has subsequently become the basis for 3 PhD projects that are now completed. From 2018, a new "budding" project was funded by the South-Eastern Norway Regional Health Authority; the AgeSUD project, which is a collaboration between Sørlandet Hospital and SERAF. AgeSUD uses registry data linked to the clinical cohort data from NorCOMT. The project aims to improve knowledge about the effect of substance abuse treatment, including OMT, health promotion and knowledge about an aging substance abuse population.

In 2021, SERAF has been commissioned by the Norwegian Directorate of Health to evaluate the implementation of the revised guideline for OMT. The evaluation is currently funded until 31.12.2024.

The assignment SERAF has received from the Directorate of Health is twofold:

1. Evaluate whether the guideline leads to changes in clinical practice, user involvement and patient satisfaction.
2. Generally highlight challenges and success factors related to the implementation of the revised guideline.

### Evaluation of Heroin Assisted Treatment (HAT) and quality of life in HAT

In 2020, SERAF was awarded the responsibility of leading the evaluation of the Heroin Assisted Treatment pilot project. SERAF was awarded funding to lead the evaluation after an open competition with several participants. The project will be carried out together with a large and highly competent partner group consisting of; Rusforsk at Oslo University Hospital, Bergen Addiction Research (BAR) in Helse Bergen, Center for Alcohol and Drug Research (CRF) at Aarhus University and the user organization proLARNett. The core of the project, as we see it, is to contribute to generating new knowledge about the benefits of this new form of treatment, heroin-assisted treatment in Norway.

In 2021, SERAF was awarded funding from the DAM Foundation for a study on quality of life in HAB. A research fellow will be appointed in 2022 to help carry out the study.

### Naloxone nasal spray; overdose antidote

The Naloxone project started as part of the National Overdose Strategy (2014 - 2017), which was launched by the Norwegian Government and Minister of Health Bent Høie in 2014. The project has now been continued in the National Overdose Strategy II (2019 - 2022). The project consists of two parts: the distribution project and an accompanying research and evaluation project. The research

project looks at whether naloxone can have an overdose-reducing effect, through training in the use and distribution of naloxone nasal spray as an emergency treatment for opioid overdoses. Visit the website [www.nalokson.uio.no](http://www.nalokson.uio.no) for more information.

The distribution project, which is ongoing, contributed to more than 5,000 naloxone nasal sprays being distributed in more than 50 Norwegian municipalities in 2021.

In 2021, funding for the project was increased, enabling more municipalities and target groups to be included in the project

## PriSUD

PriSUD is a project that was developed and founded at SERAF from around 2011, including the NorMA project, and is now a larger collaborative project with several partners and funding sources. PriSUD is the first longitudinal study to examine inmates with substance use disorders in three Nordic countries. The overall goal of PriSUD is to develop new knowledge that contributes to better mental and physical health, improved quality of life among people with substance use disorders in prison. The project aims to examine inmates in three different periods related to imprisonment: the time before imprisonment, the time during imprisonment and after release. The project has two main parts: PriSUD-Norway and PriSUD-North, each with their own funding sources. The project uses both collected cohort data and register data as part of the data basis.

In 2021, several new positions have been appointed in the PriSUD project, including a research fellow and a postdoc with a workplace at SERAF.

## Opioid painkillers and POINT

For a number of years, SERAF has worked on issues related to opioid painkillers and associated problems. Most projects have used data from the Norwegian Prescription Database, and this has included Nordic collaboration. In 2019, SERAF received funding from the Norwegian Directorate of Health's National Overdose Strategy to investigate the role of opioid painkillers in the development of problems and overdose mortality. In 2020, SERAF was awarded funding from the Norwegian Research Council for the project Preventing an Opioid Epidemic In Norway: Focusing on Treatment of Chronic pain (POINT), which is led by Professor Svetlana Skurtveit. The project aims to help prevent a potential opioid epidemic in Norway. The overall goal of the POINT project is to study how doctors who write prescriptions for opioid pain medication can optimize the treatment of patients with chronic pain.

In 2021, several new positions have been added to the POINT project, including a research fellow and a researcher with a workplace at SERAF.

## Various smaller projects, activities and collaborations

SERAF is involved in a number of other externally funded projects as a partner: This applies to involvement in the NFR project CARE, where SERAF has a researcher employed on external project funding. Similarly, SERAF has been a partner in an NFR project called Fritt valg, where we have had a researcher in a 50% position. SERAF is also involved in other collaborations and research activities. SERAF researchers are also involved in projects related to IPOT at OUS. SERAF contributes to Naltrekson projects that are now mainly anchored at AHUS, but which have previously been developed and led by SERAF.

## Collaboration (national and international)

Most of SERAF's projects include extensive collaboration with national and international players in the field. Collaboration takes place both directly in the form of joint project funding, research and project development. Professor Thomas Clausen is a national expert member from Norway for EMCDDA's work on drug-related deaths and through this collaboration has ongoing contact with national experts and a broad international network from all EU countries on the topic.

SERAF has partnerships and collaborations with several international players in the field of substance abuse through our projects. In the Nalokson project, we collaborate with King's College in London. In the HAB project, we collaborate with Aarhus University and the Center for Alcohol and Drug Research. In the PriSUD project, we collaborate with Karolinska Institutet and Aarhus University, and we collaborate on OMT and opioid research with Charles University, Prague, in the Czech Republic, to name just a few of our international partners.

## User participation

SERAF has established user participation partnerships in all our projects. In new projects, relevant user organizations are invited to participate in the planning phase and in the development of projects. Funding applications include funding for user participation activities in the projects. In ongoing project work, user participation includes both data collection and interpretation of results, as well as dissemination and publication. SERAF is in ongoing dialogue and good cooperation with a number of organizations in the field of substance abuse in Norway.

## Outreach and communication

---

### Further education courses and seminars

As part of the assignment from the Norwegian Directorate of Health, SERAF is responsible for competence enhancement in the field of substance abuse. One of the ways in which SERAF does this is by organizing annual university courses in further and continuing education in substance abuse and addiction medicine. There are primarily two courses that are arranged: the University Course in Substance Abuse Medicine and the Advanced Course in Substance Abuse and Psychiatry. In addition, SERAF employees give a number of lectures each year, both at the medical school at the University of Oslo and for other groups.

SERAF was present at Arendalsuka 2021 and contributed to a seminar on OMT in Norway.

In 2021, SERAF has taken over the role of organizer of the national LAR conference to be held in October 2022. Work on the conference is well underway and partners in the conference include Oslo Municipality, OUS and ProLAR Nett.

Several seminars and conferences that SERAF was involved in were also canceled in 2021 due to the pandemic.

### Doctoral theses

Almost 40 PhD candidates have submitted and completed their doctoral thesis at SERAF over the years from 2007 to the present. In 2021, 1 dissertation was submitted with supervision from SERAF and the public defense is planned for 2022.

An overview of doctoral theses can be found on SERAF's website:

<https://www.med.uio.no/klinmed/forskning/sentre/seraf/publikasjoner/doktoravhandlingar/>

SERAF's scientific staff are currently supervising a number of ongoing PhD projects, which are expected to lead to PhD dissertations in the years to come.

### E-learning and video

At SERAF, we have been working for several years with e-health interventions, video and animated films as tools. Together with the Department of Psychology, SERAF has established an e-health platform that can be used in interventions aimed at behavioral change. The starting point for the interventions is a smoking cessation program, developed at SERAF, which has been further developed to also be used in behavioral change related to quitting opioid painkillers or other drugs.

SERAF has further developed and updated an e-learning program on the use of naloxone nasal spray, linked to the Naloxone project. The e-learning course in the Naloxone project is very popular and helps us to reach the target group throughout Norway. The course is available to everyone on the website [naloksonkurs.no](http://naloksonkurs.no)

### SERAF as a consultation body in 2021

In 2021, SERAF's employees have contributed the following consultation responses:

- Consultation response to the revised national professional guideline on treatment of opioid dependence
- Consultation on a proposal for a temporary amendment to the regulations on the prescription and dispensing of medicines from pharmacies

## Publications

---

### Reports and knowledge summaries

- SERAF report 1/2021 - Prevention of Covid-19 at the LAR organizations in 2020 - Experiences and measures
- SERAF report 2/2021 - Opioid analgesics as a starting point for OMT in Norway 2020
- Use, possession and drink-driving among inmates in Norwegian prisons 2000-2019
- SERAF report no 4/2021 - Status report 2020

### Scientific articles in 2021

**In 2021, 49 scientific articles have been registered on Cristin.no with contributions from SERAF**

Aas, Christer Frode; Vold, Jørn Henrik; Gjestad, Rolf; Skurtveit, Svetlana; Lim, Aaron G.; Gjerde, Kristian Varden; Løberg, Else-Marie; Johansson, Kjell Arne; Fadnes, Lars T..

Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. *Substance Abuse Treatment, Prevention, and Policy* 2021; Volume 16. FHI HAUKELAND UiB UiO

Andersen, Jannike Mørch; Bogen, Inger Lise; Karinen, Ritva Anneli; Brochmann, Gerd-Wenche; Mørland, Jørg Gustav; Vindenes, Vigdis; Boix Escolan, Fernando.

Does the preparation for intravenous administration affect the composition of heroin injections? A controlled laboratory study. *Addiction* 2021 Volume 116.(11) p.3104-3112  
UiO OUS FHI

Bech, Anne Berit; Clausen, Thomas; Waal, Helge; Delaveris, Gerd Jorunn Møller; Skeie, Ivar.

Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study. *Addiction* 2021 p.1-9  
UiO SI OUS

Bramness, Jørgen G.; Hjellvik, Vidar; Stubhaug, Audun; Skurtveit, Svetlana.

Possible opioid-saving effect of cannabis-based medicine using individual-based data from the Norwegian Prescription Database. *Basic & Clinical Pharmacology & Toxicology* 2021 p.1-9  
FHI UiT UiO OUS

Brenna, Ida Halvorsen; Marciuch, Anne; Birkeland, Bente; Veseth, Marius; Røstad, Bente; Løberg, Else-Marie; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad; Weimand, Bente.

'Not at all what I had expected!': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. *Journal of Substance Abuse Treatment* 2021 p.1-11  
HAUKELAND UiB UiO UIA OSLOMET USN AHUS SIV

Bukten, Anne; Stavseth, Marianne Riksheim.

Suicide in prison and after release: a 17-year national cohort study. *European Journal of Epidemiology (EJE)* 2021 p.1-9  
UiO OUS

Burdzovic, Jasmina; Torvik, Fartein Ask; Ystrøm, Eivind; Skurtveit, Svetlana; Handal, Marte; Martinez, Priscilla; Laslett, Anne-Marie; Lund, Ingunn Olea.

Parental Risk Constellations and Future Alcohol Use Disorder (AUD) in Offspring: A Combined HUNT Survey and Health Registries Study. *Psychology of Addictive Behaviors* 2021  
UiO FHI

Chalabianloo, Fatemeh; Fadnes, Lars T.; Høiseth, Gudrun; Ohldieck, Christian; Vold, Jørn Henrik; Aas, Christer Frode; Løberg, Else-Marie; Johansson, Kjell Arne; Bramness, Jørgen Gustav.  
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. *Substance Abuse Treatment, Prevention, and Policy* 2021; Volume 16. p.1-8  
UiB HAUKELAND UiO DIAKON OUS UiT FHI

Degerud, Eirik Magnus Meek; Høiseth, Gudrun; Mørland, Jørg; Ariansen, Inger Kristine Holtermann; Graff-Iversen, Sidsel; Ystrøm, Eivind; Zuccolo, Luisa; Tell, Grethe S.; Næss, Øyvind.  
Associations of Binge Drinking With the Risks of Ischemic Heart Disease and Stroke: A Study of Pooled Norwegian Health Surveys. *American Journal of Epidemiology* 2021; Volume 190.(8) p.1592-1603  
DIAKON OUS UiB FHI UiO STAMI

Ellingsen, Maren Mikkelsen; Clausen, Thomas; Johannesen, Sunniva Launes; Martinsen, Egil W.; Hallgren, Mats.  
Effects of acute exercise on drug craving in adults with poly-substance use disorder. A randomized controlled trial. *Mental Health and Physical Activity* 2021; Volume 21. p.1-9  
OUS UiO

Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Leiva, Rafael Alexander Mo; Ohldieck, Christian; Chalabianloo, Fatemeh; Skurtveit, Svetlana Ondrasova; Lygren, Ole Jørgen Scheie; Dalgard, Olav; Vickerman, Peter; Midgard, Håvard; Løberg, Else-Marie; Johansson, Kjell Arne.  
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). *PLoS Medicine* 2021; Volume 18.(6)  
UiB HAUKELAND UiO FHI AHUS OUS

Finstad, Jeanette; Røise, Olav; Rosseland, Leiv Arne; Clausen, Thomas; Havnes, Ingrid Amalia.  
Discharge from the trauma center: exposure to opioids, unmet information needs and lack of follow up- a qualitative study among physical trauma survivors. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine* 2021; Volume 29.(1) p.1-12  
OUS UiO

Fredheim, Olav Magnus; Skurtveit, Svetlana Ondrasova; Sjøgren, Per; Aljabri, Mohammad Belal; Hjellvik, Vidar.  
Prescriptions of analgesics during chronic cancer disease trajectories: A complete national cohort study. *Pharmacoepidemiology and Drug Safety* 2021; Volume 30.(11) p.1504-1513  
NTNU STO AHUS UiO FHI

Gabrhelík, Roman; Handal, Marte; Mravík, Viktor; Nechanská, Blanka; Tjagvad, Christian; Thylstrup, Birgitte; Hesse, Morten; Minaík, Jakub; Jarkovský, Jí; Bukten, Anne; Clausen, Thomas; Skurtveit, Svetlana.  
Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. *BMJ Open* 2021; Volume 11.(5) p.1-8  
FHI UiO

Gaulen, Zhanna; Brenna, Ida Halvorsen; Fadnes, Lars T.; Saltyte Benth, Jurate; Solli, Kristin Klemmetsby; Kunøe, Nikolaj; Opheim, Arild; Tanum, Lars Håkon Reiestad.  
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. *European Addiction Research* 2021; Volume 28.(1) p.56-67  
LDS OSLOMET HAUKELAND UiB UiO AHUS SIV



Hamina, Aleksj; Handal, Marte; Fredheim, Olav; Clausen, Thomas; Chen, Li-Chia; Skurtveit, Svetlana Ondrasova.

Filled prescriptions for opioids among children and adolescents - A nationwide study from 2010 to 2018. *Acta Anaesthesiologica Scandinavica* 2021; Volume 65.(10) p.1475-1483

UiO FHI NTNU STO AHUS

Hesse, Morten; Thylstrup, Birgitte; Seid, Abdu Kedir; Tjagvad, Christian; Clausen, Thomas.

A retrospective cohort study of medication dispensing at pharmacies: Administration matters. *Drug and Alcohol Dependence* 2021; Volume 225.

UiO

Holmberg, Siril Therese; Fredheim, Olav Magnus; Skurtveit, Svetlana Ondrasova; Salvesen, Øyvind; Nygaard, Øystein Petter; Gulati, Agnete Malm; Solberg, Tore; Gulati, Sasha.

Persistent Use of Prescription Opioids Following Lumbar Spine Surgery: Observational Study with Prospectively Collected Data from Two Norwegian Nationwide Registries. *Spine* 2021 p.1-

18 UNN FHI STO AHUS HN NTNU UiO

Holter, Marianne Therese Smogeli.

A free choice of treatment - Conditions for and the importance of freedom of choice in the specialist health service. *Nytt Norsk Tidsskrift* 2021; Volume 38.(4) p.298- 307

UiO

Høiseth, Gudrun; Hilberg, Thor; Trydal, Torleif; Husa, Asgeir; Vindenes, Vigdis; Bogstrand, Stig Tore.

The alcohol marker phosphatidylethanol is closely related to AST, GGT, ferritin and HDL-C. *Basic & Clinical Pharmacology & Toxicology* 2021 p.1-9

UiO DIAKON OUS

Jørgenrud, Benedicte Marie; Kabashi, Saranda; Nadezhdin, Aleksei; Bryun, Evgeny; Koshkina, Evgenya; Tetenova, Elena; Lerdal, Anners; Nordby, Gudmund; Kolgashkin, Alexey; Petukhov, Alexei; Perekhodov, Sergey; Davydova, Elena; Vindenes, Vigdis; Gamboa, Danil; Bogstrand, Stig Tore.

The Association between the Alcohol Biomarker Phosphatidylethanol (PEth) and Self-Reported Alcohol Consumption among Russian and Norwegian Medical Patients. *Alcohol and Alcoholism* 2021; Volume 56.(6) p.726-736

OUS UiO LDS

Karlsson, Ann Tarja; Vederhus, John-Kåre; Clausen, Thomas; Weimand, Bente; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad.

Levels of impulsivity, hyperactivity, and inattention and the association with mental health and substance use severity in opioid-dependent patients seeking treatment with extended-release naltrexone. *Journal of Clinical Medicine* 2021; Volume 10.(19) p.1-9

SSHF UiO USN AHUS SIV OSLOMET

Kruckow, Line; Tjagvad, Christian; Clausen, Thomas; Banner, Jytte.

Psychiatric disorders in a population of deceased drug users. *Nordic Journal of Psychiatry* 2021

UiO

Latif, Zill-E-Huma; Skjærvø, Ingeborg; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad.

Chronic Pain Among Patients With an Opioid Use Disorder. *American Journal on Addictions* 2021; Volume 30.(4) p.366-375

AHUS OSLOMET UiO NKVTS SIV

Lien, Lars; Bergem, Anne Kristine.

Psychiatry needs a boost - not empty promises *Journal of the Norwegian Medical Association*

2021 OSLOMET SI UiO

Lindstad, Marianne; Skurtveit, Svetlana; Bukten, Anne.  
Too much or too little medication? A national study of prescribed psychotropic drugs among inmates in Norwegian prisons. *Norwegian Epidemiology* 2021; Volume 29.(1-2) p.85-95  
UiO FHI OUS

Lokdam, Nicoline; Stavseth, Marianne Riksheim; Bukten, Anne.  
Exploring the external validity of survey data with triangulation: A case study from the Norwegian Offender Mental Health and Addiction (NorMA) Study. *Research Methods in Medicine & Health Sciences* 2021; Volume 2.(5) p.140-147  
OUS UiO

McDonald, Rebecca; Parkin, Stephen; Eide, Desiree Soraya; neale, joanne; Clausen, Thomas; Metrebian, Nicola; Carter, Ben; Strange, John.  
Rethinking 'carriage' of take-home naloxone. *International journal of drug policy* 2021  
UiO

Midgard, Håvard; Ulstein, Kjersti Anne; Backe, Øystein; Foshaug, Tarjei; Sørli, Hanne; Vennesland, Kristin; Nilssen, David; Dahl, Elin Hoffmann; Finbråten, Ane-Kristine; Wüsthoff, Linda Elise; Dalgard, Olav.  
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. *International journal of drug policy* 2021; Volume 96.  
OUS AHUS HAUKELAND LDS UiO

Midtlyng, Lena; Høiseth, Gudrun; Luytkis, Hege Cathrine; Kristoffersen, Lena; Nygaard, Ilah Le; Strand, Maren; Arnestad, Marianne; Vevelstad, Merete.  
Relationship between betahydroxybutyrate (BHB) and acetone concentrations in postmortem blood and cause of death. *Forensic Science International* 2021; Volume 321:110726. p.1-6  
OUS UiO DIAKON

Moe, Jenny Skumsnes; Bolstad, Ingeborg; Mørland, Jørg Gustav; Bramness, Jørgen Gustav.  
GABAA subunit single nucleotide polymorphisms show sex-specific association to alcohol consumption and mental distress in a Norwegian population-based sample. *Psychiatry Research* 2021; Volume 307.  
UiO UiT FHI SI

Odsbu, Ingvild; Handal, Marte; Hjellvik, Vidar; Borchgrevink, Petter Chr.; Clausen, Thomas; Hamina, Aleksii; Lid, Torgeir Gilje; Nesvåg, Ragnar; Skurtveit, Svetlana Ondrasova.  
Use of other addictive drugs among opioid users with long-term pain. *Norwegian Epidemiology* 2021; Volume 29.(1-2) p.45-53  
FHI STO NTNU UiO UIS SUS

Odsbu, Ingvild; Mahic, Milada; Skurtveit, Svetlana Ondrasova; Lund, Ingunn Olea; Handal, Marte.  
An 11-year nationwide registry-linkage study of opioid maintenance treatment in pregnancy in Norway. *Norwegian Epidemiology* 2021; Volume 29.(1-2) p.63-70  
FHI UiO

Opheim, Arild; Gaulen, Zhanna; Solli, Kristin Klemmetsby; Latif, Zill-E-Huma; Fadnes, Lars T.; Saltyte Benth, Jurate; Kunøe, Nikolaj; Tanum, Lars.  
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. *American Journal on Addictions* 2021; Volume 30.(5) p.453-460  
UiB HAUKELAND UiO SIV AHUS LDS OSLOMET

Oshaug, Katja; Kronstrand, Robert; Kugelberg, Fredrik C.; Kristoffersen, Lena; Mørland, Jørg Gustav; Høiseth, Gudrun.

Frequency of postmortem ethanol formation in blood, urine and vitreous humor - Improving diagnostic accuracy with the use of ethylsulphate and putrefactive alcohols. *Forensic Science International* 2021; Volume 331.

OUS DIAKON FHI UiO

Pape, Hilde Elisabeth; Rossow, Ingeborg Margrete; Bukten, Anne.

Are short AUDIT screeners effective in identifying unhealthy drinking of varying severity? A prison population study. *Drug and Alcohol Dependence* 2021; Volume 229.(Part B) p.1-7

FHI UiO KRUS

Pharm, Shin J.Liau B; Lalic, Samanta; Sluggett, Janet K.; Cesari, Matteo; Onder, Graziano; Hamina, Aleks; Johnell, Kristina; Tan, Edwin C.K.; Visvanathan, Renuka; Bell, J. Simon.

Medication Management in Frail Older People: Consensus Principles for Clinical Practice, Research, and Education. *Journal of the American Medical Directors Association* 2021; Volume 22.(1)

UiO

Ruud, Torleif; Drake, Robert E.; Saltyte Benth, Jurate; Drivenes, Karin; Hartveit, Miriam; Heiervang, Kristin Sverdvik; Høifødt, Tordis Sørensen; Haaland, Vegard Øksendal; Joa, Inge; Johannessen, Jan Olav; Johansen, Karl Johan; Stensrud, Bjørn; Haugom, Espen Woldsengen; Clausen, Hanne Kristin; Biringer, Eva Aaker; Bond, Gary R.

The Effect of Intensive Implementation Support on Fidelity for Four EvidenceBased Psychosis Treatments: A Cluster Randomized Trial. *Administration and Policy in Mental Health and Mental Health Services Research* 2021; Volume 48. p.909-920

UiO UiB AHUS APOTEKSØ UiT UNN HELSEFONNA SSHF SUS SI UIS

Ruud, Torleif; Haugom, Espen Woldsengen; Pincus, Harold Alan; Hynnekleiv, Torfinn.

Measuring Seclusion in Psychiatric Intensive Care: Development and Measurement Properties of the Clinical Seclusion Checklist. *Frontiers in Psychiatry* 2021; Volume 12.

AHUS UiO SI

Røgeberg, Ole; Bergsvik, Daniel; Clausen, Thomas.

Opioid overdose deaths and the expansion of opioid agonist treatment: a population-based prospective cohort study. *Addiction* 2021 p.1-9

FHI FRISCH UiO

Saberi Zafarghandi, Mohammad Bagher; Eshрати, Sahar; Rashedi, Vahid; Vameghi, Meroe; Arezoomandan, Reza; Clausen, Thomas; Waal, Helge.

Indicators of Drug-Related Community Impacts of Open Drug Scenes: A Scoping Review. *European Addiction Research* 2021

UiO

Sarfi, Annamaria Monika; Eikemo, Marie; Welle-Strand, Gabrielle; Muller, Ashley Elizabeth; Lehmann, Stine.

Mental health and use of health care services in opioidexposed schoolaged children compared to foster children. *European Child and Adolescent Psychiatry* 2021 p.1-15

UiO VV FHI NORCE UiB

Skjærvø, Ingeborg; Clausen, Thomas; Skurtveit, Svetlana Ondrasova; Bukten, Anne.

Desistance from crime following substance use treatment: the role of treatment retention, social network and self-control. *BMC Psychiatry* 2021; Volume 21. p.1-12

AHUS UiO FHI

Skurtveit, Svetlana Ondrasova.

How to avoid an opioid epidemic in Norway: Focus on treatment of long-term pain. *Glimt* 2021; Volume 2.(1) p.26-27

UiO FHI

Stenehjem, Jo Steinson; Røise, Olav; Nordseth, Trond; Clausen, Thomas; Natvig, Bård; Skurtveit, Svetlana Ondrasova; Eken, Torsten; Kristiansen, Thomas; Gran, Jon Michael; Rosseland, Leiv Arne.

Injury Prevention and long-term Outcomes following Trauma - The IPOT project: a protocol for prospective nationwide registry-based studies in Norway. *BMJ Open* 2021; Volume 11.(5)

FHI OUS UiO KREFTREG UIS NTNU STO

Torp, Henrik Andreas; Skurtveit, Svetlana Ondrasova; Skaga, Nils Oddvar; Gustavsen, Ingebjørg G.; Gran, Jon Michael; Rosseland, Leiv Arne.

Pre-injury dispensing of psychoactive prescription drugs in a ten years trauma population: a retrospective registry analysis. *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine* 2021; Volume 29. OUS UiO FHI

Tveito, Marit; Høiseth, Gudrun; Haslemo, Tore; Molden, Espen; Smith, Robert Løvsletten.

Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients. *European Journal of Clinical Pharmacology* 2021; Volume 77.(9) p.1201-1208

SIV DIAKON UiO OSLOMET OUS

Tverdal, Aage; Høiseth, Gudrun; Magnus, Per; Næss, Øyvind; Selmer, Randi; Knudsen, Gun Peggy; Mørland, Jørg.

Alcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study including 250,010 Participants. *Alcohol and Alcoholism* 2021; Volume 56.(6) p.718-725

FHI UiO OUS DIAKON

Weimand, Bente; Solli, Kristin Klemmetsby; Reichelt, Wenche Hellenen; Tanum, Lars Håkon Reiestad.

Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). *Contemporary Clinical Trials Communications* 2021; Volume 21.

SIV USN OSLOMET UiO AHUS